The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Open accessAbstract
BACKGROUND: In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of sustained virologic response among previously untreated patients with hepatitis C virus (HCV) genotype 1 infection. METHODS: We conducted a phase 3, open-label study involving previously untreated patients with chronic HCV genotype 1 infection. Patients were randomly assigned in a 1:1:1:1 ratio to receive ledipasvir and sofosbuvir in a fixed-dose combination tablet once daily for 12 weeks, ledipasvir-sofosbuvir plus ribavirin for 12 weeks, ledipasvir-sofosbuvir for 24 weeks, or ledipasvir-sofosbuvir plus ribavirin for 24 weeks. The primary end point was a sustained virologic response at 12 weeks after the end of therapy. RESULTS: Of the 865 patients who underwent randomization and were treated, 16% had cirrhosis, 12% were black, and 67% had HCV genotype 1a infection. The rates of sustained virologic response were 99% (95% confidence interval [CI], 96 to 100) in the group that received 12 weeks of ledipasvir-sofosbuvir; 97% (95% CI, 94 to 99) in the group that received 12 weeks of ledipasvir-sofosbuvir plus ribavirin; 98% (95% CI, 95 to 99) in the group that received 24 weeks of ledipasvir-sofosbuvir; and 99% (95% CI, 97 to 100) in the group that received 24 weeks of ledipasvir-sofosbuvir plus ribavirin. No patient in either 12-week group discontinued ledipasvir-sofosbuvir owing to an adverse event. The most common adverse events were fatigue, headache, insomnia, and nausea. CONCLUSIONS: Once-daily ledipasvir-sofosbuvir with or without ribavirin for 12 or 24 weeks was highly effective in previously untreated patients with HCV genotype 1 infection. (Funded by Gilead Sciences; ION-1 ClinicalTrials.gov number NCT01701401.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Poordad, F., McCone, J., Bacon, B. R., Bruno, S., Manns, M. P., Sulkowski, M. S., Jacobson, I. M., Reddy, K. R., Goodman, Z. D., Boparai, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010494 · Cited by 2,520
Self-citationTelaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Jacobson, I. M., McHutchison, J. G., Dusheiko, G., Di Bisceglie, A. M., Reddy, K. R., Bzowej, N. H., Marcellin, P., Muir, A. J., Ferenci, P., Flisiak, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012912 · Cited by 2,398
Self-citationBoceprevir for Previously Treated Chronic HCV Genotype 1 Infection
Bacon, B. R., Gordon, S. C., Lawitz, E., Marcellin, P., Vierling, J. M., Zeuzem, S., Poordad, F., Goodman, Z. D., Sings, H. L., Boparai, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009482 · Cited by 1,626
Self-citationTelaprevir for Retreatment of HCV Infection
Zeuzem, S., Andreone, P., Pol, S., Lawitz, E., Diago, M., Roberts, S., Focaccia, R., Younossi, Z., Foster, G. R., Horban, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013086 · Cited by 1,546
Self-citationLedipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Afdhal, N., Reddy, K. R., Nelson, D. R., Lawitz, E., Gordon, S. C., Schiff, E., Nahass, R., Ghalib, R., Gitlin, N., Herring, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316366 · Cited by 1,307
Self-citationLedipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Kowdley, K. V., Gordon, S. C., Reddy, K. R., Rossaro, L., Bernstein, D. E., Lawitz, E., Shiffman, M. L., Schiff, E., Ghalib, R., Ryan, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402355 · Cited by 1,130
Self-citationSofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Jacobson, I. M., Gordon, S. C., Kowdley, K. V., Yoshida, E. M., Rodriguez-Torres, M., Sulkowski, M. S., Shiffman, M. L., Lawitz, E., Everson, G., Bennett, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214854 · Cited by 1,090
Self-citationGhany, M. G., Nelson, D. R., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2011) · Hepatology · doi:10.1002/hep.24641 · Cited by 1,076
McHutchison, J. G., Manns, M., Patel, K., Poynard, T., Lindsay, K. L., Trepo, C., Dienstag, J., Lee, W. M., Mak, C., Garaud, J., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.35950 · Cited by 969
Self-citationLawitz, E., Poordad, F. F., Pang, P. S., Hyland, R. H., Ding, X., Mo, H., Symonds, W. T., McHutchison, J. G., & Membreno, F. E. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62121-2 · Cited by 547
Self-citation
Cited by
EASL Recommendations on Treatment of Hepatitis C 2018
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.026 · Cited by 2,827
Self-citationLlovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Panel, A. H. G. (2015) · Hepatology · doi:10.1002/hep.27950 · Cited by 1,382
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Afdhal, N., Reddy, K. R., Nelson, D. R., Lawitz, E., Gordon, S. C., Schiff, E., Nahass, R., Ghalib, R., Gitlin, N., Herring, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316366 · Cited by 1,307
Self-citationEASL Recommendations on Treatment of Hepatitis C 2015
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.03.025 · Cited by 1,156
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Kowdley, K. V., Gordon, S. C., Reddy, K. R., Rossaro, L., Bernstein, D. E., Lawitz, E., Shiffman, M. L., Schiff, E., Ghalib, R., Ryan, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402355 · Cited by 1,130
Self-citationEASL Recommendations on Treatment of Hepatitis C 2016
(2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.09.001 · Cited by 985
Molecular biology of hepatitis B virus infection
Seeger, C., & Mason, W. S. (2015) · Virology · doi:10.1016/j.virol.2015.02.031 · Cited by 866
Charlton, M., Everson, G. T., Flamm, S. L., Kumar, P., Landis, C., Brown, R. S., Fried, M. W., Terrault, N. A., O'Leary, J. G., Vargas, H. E., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.010 · Cited by 802
Self-citationOrganic Carbamates in Drug Design and Medicinal Chemistry
Ghosh, A. K., & Brindisi, M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501371s · Cited by 739
Panel, A.-I. H. G., Chung, R. T., Ghany, M. G., Kim, A. Y., Marks, K. M., Naggie, S., Vargas, H. E., Aronsohn, A. I., Bhattacharya, D., Broder, T., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy585 · Cited by 717
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review
Falade-Nwulia, O., Suarez-Cuervo, C., Nelson, D. R., Fried, M. W., Segal, J. B., & Sulkowski, M. S. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2575 · Cited by 688
Roth, D., Nelson, D. R., Bruchfeld, A., Liapakis, A., Silva, M., Monsour, H., Martin, P., Pol, S., Londoño, M.-C., Hassanein, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00349-9 · Cited by 671
Williams, R., Aspinall, R., Bellis, M., Camps-Walsh, G., Cramp, M., Dhawan, A., Ferguson, J., Forton, D., Foster, G., Gilmore, S. I., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61838-9 · Cited by 602
Self-citationZeuzem, S., Ghalib, R., Reddy, K. R., Pockros, P. J., Ari, Z. B., Zhao, Y., Brown, D. D., Wan, S., DiNubile, M. J., Nguyen, B.-Y., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0785 · Cited by 516
Self-citationFoster, G. R., Irving, W. L., Cheung, M. C. M., Walker, A. J., Hudson, B. E., Verma, S., McLauchlan, J., Mutimer, D. J., Brown, A., Gelson, W. T. H., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.029 · Cited by 492
Self-citationEstimating Prevalence of Hepatitis C Virus Infection in the United States, 2013‐2016
Hofmeister, M. G., Rosenthal, E. M., Barker, L. K., Rosenberg, E. S., Barranco, M. A., Hall, E. W., Edlin, B. R., Mermin, J., Ward, J. W., & Ryerson, A. B. (2019) · Hepatology · doi:10.1002/hep.30297 · Cited by 486
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1
Naggie, S., Cooper, C., Saag, M., Workowski, K., Ruane, P., Towner, W. J., Marks, K., Luetkemeyer, A., Baden, R. P., Sax, P. E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501315 · Cited by 470
Self-citationPoordad, F., Schiff, E. R., Vierling, J. M., Landis, C., Fontana, R. J., Yang, R., McPhee, F., Hughes, E. A., Noviello, S., & Swenson, E. S. (2016) · Hepatology · doi:10.1002/hep.28446 · Cited by 460
Treatment of Hepatitis C: A Systematic Review
Kohli, A., Shaffer, A., Sherman, A., & Kottilil, S. (2014) · JAMA · doi:10.1001/jama.2014.7085 · Cited by 426
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
Sarrazin, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.09.011 · Cited by 423
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1
Wyles, D. L., Ruane, P. J., Sulkowski, M. S., Dieterich, D., Luetkemeyer, A., Morgan, T. R., Sherman, K. E., Dretler, R., Fishbein, D., Gathe, J. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503153 · Cited by 419
Global epidemiology and burden of HCV infection and HCV-related disease
Thrift, A. P., El-Serag, H. B., & Kanwal, F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.176 · Cited by 382
Manns, M., Pol, S., Jacobson, I. M., Marcellin, P., Gordon, S. C., Peng, C.-Y., Chang, T.-T., Everson, G. T., Heo, J., Gerken, G., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61059-x · Cited by 342
Self-citationChhatwal, J., Kanwal, F., Roberts, M. S., & Dunn, M. A. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1336 · Cited by 338
Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients
Woolley, A. E., Singh, S. K., Goldberg, H. J., Mallidi, H. R., Givertz, M. M., Mehra, M. R., Coppolino, A., Kusztos, A. E., Johnson, M. E., Chen, K., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812406 · Cited by 335
From non-A, non-B hepatitis to hepatitis C virus cure
Pawlotsky, J.-M., Feld, J. J., Zeuzem, S., & Hoofnagle, J. H. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.006 · Cited by 328
Self-citationKoh, C., Li, Q., & Liang, J. (2016) · Clinical Virology · doi:10.1128/9781555819439.ch54 · Cited by 321
Lawitz, E., Gane, E., Pearlman, B., Tam, E., Ghesquiere, W., Guyader, D., Alric, L., Bronowicki, J.-P., Lester, L., Sievert, W., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61795-5 · Cited by 299
Hepatitis C virus drug resistance–associated substitutions: State of the art summary
Lontok, E., Harrington, P., Howe, A., Kieffer, T., Lennerstrand, J., Lenz, O., McPhee, F., Mo, H., Parkin, N., Pilot‐Matias, T., et al. (2015) · Hepatology · doi:10.1002/hep.27934 · Cited by 275
Self-citationvan der Meer, A. J., Feld, J. J., Hofer, H., Almasio, P. L., Calvaruso, V., Fernández-Rodríguez, C. M., Aleman, S., Ganne-Carrié, N., D’Ambrosio, R., Pol, S., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.10.017 · Cited by 274
Lens, S., Alvarado-Tapias, E., Mariño, Z., Londoño, M.-C., LLop, E., Martinez, J., Fortea, J. I., Ibañez, L., Ariza, X., Baiges, A., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.07.016 · Cited by 271
Challenges to Liver Transplantation and Strategies to Improve Outcomes
Dutkowski, P., Linecker, M., DeOliveira, M. L., Müllhaupt, B., & Clavien, P.-A. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.08.045 · Cited by 270
Hézode, C., Asselah, T., Reddy, K. R., Hassanein, T., Berenguer, M., Fleischer-Stepniewska, K., Marcellin, P., Hall, C., Schnell, G., Pilot-Matias, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60159-3 · Cited by 259
Self-citationReddy, K. R., Bourlière, M., Sulkowski, M., Omata, M., Zeuzem, S., Feld, J. J., Lawitz, E., Marcellin, P., Welzel, T. M., Hyland, R., et al. (2015) · Hepatology · doi:10.1002/hep.27826 · Cited by 255
Self-citationHepatitis C virus screening among children exposed during pregnancy.
Chappell, C. A., Hillier, S. L., Crowe, D., Meyn, L. A., Bogen, D. L., & Krans, E. E. (2018) · PEDIATRICS · doi:10.1542/peds.2017-3273 · Cited by 112
Rogal, S. S., Yakovchenko, V., Waltz, T. J., Powell, B. J., Kirchner, J. E., Proctor, E. K., Gonzalez, R., Park, A., Ross, D., Morgan, T. R., et al. (2017) · Implementation Science · doi:10.1186/s13012-017-0588-6 · Cited by 98
Advances in hepatitis C therapy: what is the current state - what come's next?
Zopf, S. (2016) · World Journal of Hepatology · doi:10.4254/wjh.v8.i3.139 · Cited by 91
Hepatic decompensation during direct-acting antiviral therapy of chronic hepatitis C
Hoofnagle, J. H. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.007 · Cited by 31
Arora, S. S., Axley, P., Ahmed, Z., Satapathy, S. K., Wong, R., Kuo, Y., & Singal, A. K. (2019) · Transplant International · doi:10.1111/tri.13424 · Cited by 24
Linas, B. P., Morgan, J. R., Pho, M. T., Leff, J. A., Schackman, B. R., Horsburgh, C. R., Assoumou, S. A., Salomon, J. A., Weinstein, M. C., Freedberg, K. A., et al. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw266 · Cited by 19
Metadata
- Authors
- Afdhal, N., Zeuzem, S., Kwo, P., Chojkier, M., Gitlin, N., Puoti, M., Romero-Gomez, M., Zarski, J.-P., Agarwal, K., Buggisch, P., Foster, G. R., Bräu, N., Buti, M., Jacobson, I. M., Subramanian, G. M., Ding, X., Mo, H., Yang, J. C., Pang, P. S., Symonds, W. T., McHutchison, J. G., Muir, A. J., Mangia, A., & Marcellin, P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-15
- Volume
- 370
- Issue
- 20
- Pages
- 1889-1898
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2092646281
- Cited by
- 1,705
- References
- 14
- FWCI
- 165.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.